X. Long Zheng/LinkedIn
Sep 22, 2026, 07:18
X. Long Zheng: From ADAMTS13 to New TTP Treatment
X. Long Zheng, Professor and Chair of Pathology and Laboratory Medicine at The University of Kansas, shared a post on LinkedIn:
“I had a great time as a visiting professor at Montefiore Medical Center to meet with pathology residents/faculty and discuss the 100-year research and development in TTP (thrombotic thrombocytopenic purpura).
Progress has been particularly accelerated since the molecular identification and cloning of ADAMTS13, a key enzyme that is deficient in patients with TTP.
ADAMTS13 is now a FDA-approved drug for treatment of congenital TTP.”
Stay updated with Hemostasis Today.
-
Nov 13, 2026, 03:21Abdul Muqtadir Abbasi: Iron Deficiency Beyond Anemia and the Importance of Finding the Cause
-
Nov 13, 2026, 03:05Marc Carrier: Aspirin vs Anticoagulants for VTE Prevention After Joint Replacement
-
Nov 13, 2026, 02:28Julia Sjöberg: ROCK1 Inhibition and Red Blood Cell Recovery After Chemotherapy
-
Nov 13, 2026, 02:07Tonie Reincke: Understanding Deep Vein Thrombosis and Vascular Health
-
Nov 13, 2026, 01:52Akshita Singh: The Remarkable Process of Blood Clotting
-
Nov 12, 2026, 22:52Milka Koupenova: The Role of Platelet RIG-I in Regulating Thrombotic Responses
-
Nov 12, 2026, 22:50Arun V J: Why Has India Still Not Achieved 100% Voluntary Blood Donation?
-
Nov 12, 2026, 22:49Sickle Cell Disease Deserves to Be Prioritised in Ghana – ISCC
-
Nov 12, 2026, 22:47Samir Kumar Beura: Delighted to Serve as a Topic Editor for a Research Topic in Frontiers in Neuroscience